[Serological diagnosis for human parvovirus B19 infection by an enzyme immunoassay kit with recombinant antigens synthesized in a baculovirus expression system].
Propagation of human parvovirus B19 (B19) in cell cultures are not applicable to the source of viral antigens for serological assays at present. Enzyme immunoassay (EIA) kits with recombinant B19 capsids by E. coli or baculovirus expression system have been developed. We tested serum samples from the patients with erythema infectiosum and aplastic crisis by EIA kit with recombinant antigens synthesized in a baculovirus expression system (Denka Seiken Co., Tokyo, Japan). The antigens used in the kit are self-assembled recombinants containing both VP-1 and VP-2 with the same proportion as found in native B19 capsids. B19 IgM is detected by antibody capture methods and IgG by indirect methods. All of the samples were positive for B19 DNA by nested PCR. Thirty-six (97%) of the 37 patients with erythema infectiosum and all (100%) of the 4 patients with aplastic crisis were positive for B19 IgM. The EIA kit with recombinant antigens synthesized in a baculovirus expression system has proved to be reliable and useful for the diagnosis of B19 infection.
D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral; D016367:Baculoviridae / Q000276:immunology*; D016731:Erythema Infectiosum / Q000175:diagnosis*; D006801:Humans; D007124:Immunoenzyme Techniques; D016732:Parvovirus B19, Human / Q000276:immunology; D011933:Reagent Kits, Diagnostic / Q000592:standards; D011994:Recombinant Proteins
D000914:Antibodies, Viral; D000956:Antigens, Viral; D011933:Reagent Kits, Diagnostic; D011994:Recombinant Proteins